The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves Wegovy (semaglutide) as a tablet for weight loss, making it the first GLP-1 receptor agonist medicine in pill form approved in the UK for this purpose. Multiple outlets report the approval covers use for adults who have obesity or who are overweight with weight-related health conditions. The change provides an alternative to weekly injections for some patients and, according to one report, patients can switch directly from the weekly injection to a daily 25 mg tablet. BBC and other coverage also says that patients who meet eligibility criteria may be able to access the tablets through private prescriptions, with availability expected within weeks. Sky News and similar summaries describe the new tablet format as the first daily option for weight management in the country. Several reports note that the UK is among the jurisdictions to authorize the pill form, following approvals already granted in other countries such as the United States and the United Arab Emirates. The news coverage focuses on regulatory authorization, who can be eligible, and the expected timeline for patients to obtain the tablets.